Literature DB >> 18262468

Nicotinic receptors, allosteric proteins and medicine.

Jean-Pierre Changeux1, Antoine Taly.   

Abstract

The nicotinic acetylcholine receptor (nAChR) was the first ion channel and membrane receptor of a neurotransmitter to be isolated and chemically identified and is one of the best known membrane proteins involved in signal transduction. Subsequently, nAChRs have been a target for drug discovery because of their potential to impact numerous brain diseases and disorders. Here, we consider recent developments in our understanding of nAChR structure and of the conformational transitions that link the acetylcholine (ACh)-binding site and the ion channel to mediate fast neurotransmission. The knowledge of such allosteric mechanisms is essential to understand pathologies such as congenital myasthenia, autosomal dominant nocturnal frontal lobe epilepsies, sudden infant death syndrome, attention deficit hyperactivity disorder and nicotine addiction and to design novel therapies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18262468     DOI: 10.1016/j.molmed.2008.01.001

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  45 in total

1.  Desformylflustrabromine (dFBr) and [3H]dFBr-Labeled Binding Sites in a Nicotinic Acetylcholine Receptor.

Authors:  Ayman K Hamouda; Ze-Jun Wang; Deirdre S Stewart; Atul D Jain; Richard A Glennon; Jonathan B Cohen
Journal:  Mol Pharmacol       Date:  2015-04-13       Impact factor: 4.436

2.  Energy and structure of the M2 helix in acetylcholine receptor-channel gating.

Authors:  Archana Jha; Prasad Purohit; Anthony Auerbach
Journal:  Biophys J       Date:  2009-05-20       Impact factor: 4.033

3.  Agonist-dependent endocytosis of γ-aminobutyric acid type A (GABAA) receptors revealed by a γ2(R43Q) epilepsy mutation.

Authors:  Severine Chaumont; Caroline André; David Perrais; Eric Boué-Grabot; Antoine Taly; Maurice Garret
Journal:  J Biol Chem       Date:  2013-08-09       Impact factor: 5.157

4.  Potentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site.

Authors:  Gareth T Young; Ruud Zwart; Alison S Walker; Emanuele Sher; Neil S Millar
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-12       Impact factor: 11.205

Review 5.  Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system.

Authors:  Antoine Taly; Pierre-Jean Corringer; Denis Guedin; Pierre Lestage; Jean-Pierre Changeux
Journal:  Nat Rev Drug Discov       Date:  2009-09       Impact factor: 84.694

Review 6.  Structural basis of activation of cys-loop receptors: the extracellular-transmembrane interface as a coupling region.

Authors:  Mariana Bartos; Jeremías Corradi; Cecilia Bouzat
Journal:  Mol Neurobiol       Date:  2009-10-28       Impact factor: 5.590

Review 7.  A gating mechanism of pentameric ligand-gated ion channels.

Authors:  Nicolas Calimet; Manuel Simoes; Jean-Pierre Changeux; Martin Karplus; Antoine Taly; Marco Cecchini
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

8.  Conformational changes in alpha 7 acetylcholine receptors underlying allosteric modulation by divalent cations.

Authors:  James T McLaughlin; Sean C Barron; Jennifer A See; Robert L Rosenberg
Journal:  BMC Pharmacol       Date:  2009-01-13

9.  The nicotinic acetylcholine receptors of the parasitic nematode Ascaris suum: formation of two distinct drug targets by varying the relative expression levels of two subunits.

Authors:  Sally M Williamson; Alan P Robertson; Laurence Brown; Tracey Williams; Debra J Woods; Richard J Martin; David B Sattelle; Adrian J Wolstenholme
Journal:  PLoS Pathog       Date:  2009-07-17       Impact factor: 6.823

10.  Glutamine 57 at the complementary binding site face is a key determinant of morantel selectivity for {alpha}7 nicotinic receptors.

Authors:  Mariana Bartos; Kerry L Price; Sarah C R Lummis; Cecilia Bouzat
Journal:  J Biol Chem       Date:  2009-06-08       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.